Evidence map›Paper›PMID 41254806›Full record

Trial reportBritish journal of haematology2026

Mosunetuzumab is effective and well tolerated in older patients with relapsed/refractory follicular lymphoma: Subgroup analysis of a phase I/II study.

Swetha Kambhampati Thiruvengadam, Leslie L Popplewell, Alex F Herrera, Matthew Mei, Liana Nikolaenko, Xiaofang Zuo, Shen Yin, Mingzhu Zhou, Yong Mun, Mei Wu and 2 more

Registry-linked trialAbstract readClinical Trial, Phase IIClinical Trial, Phase IMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in British journal of haematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02500407 (An Open-Label, Multicenter, Phase I/II Trial Evaluating the Safety, Efficacy, and Pharmacokinetics of Escalating Doses of Mosunetuzumab), which is not on this map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02500407 phase1 / phase2completednot on this map

An Open-Label, Multicenter, Phase I/II Trial Evaluating the Safety, Efficacy, and Pharmacokinetics of Escalating Doses of Mosunetuzumab (BTCT4465A) as a Single Agent and Combined With Atezolizumab in Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia

TypeinterventionalSponsorGenentech, Inc.Ran2015 to 2025Enrolled713ConditionsLymphocytic Leukemia, Chronic, Lymphoma, Non HodgkinArmsBTCT4465A (Mosunetuzumab) IV, Atezolizumab, BTCT4465A (Mosunetuzumab) SC
3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Trial
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Swetha Kambhampati ThiruvengadamDepartment of Hematology/HCT, City of Hope National Medical Center, Duarte, California, USA.
Leslie L PopplewellHematology and Blood and marrow Transplant, City of Hope Cancer Center, Atlanda, George, USA.
Alex F HerreraDepartment of Hematology/HCT, City of Hope National Medical Center, Duarte, California, USA.ORCID https://orcid.org/0000-0002-9665-7415
Matthew MeiDepartment of Hematology/HCT, City of Hope National Medical Center, Duarte, California, USA.ORCID https://orcid.org/0000-0002-1109-6955
Liana NikolaenkoDepartment of Hematology/HCT, City of Hope National Medical Center, Duarte, California, USA.
Xiaofang ZuoDepartment of Hematology/HCT, City of Hope National Medical Center, Duarte, California, USA.
Shen YinGenentech, Inc., South San Francisco, California, USA.
Mingzhu ZhouF. Hoffmann-La Roche Ltd, Shanghai, China.
Yong MunGenentech, Inc., South San Francisco, California, USA.
Mei WuGenentech, Inc., South San Francisco, California, USA.
Michael C WeiGenentech, Inc., South San Francisco, California, USA.
Lihua E BuddeDepartment of Hematology/HCT, City of Hope National Medical Center, Duarte, California, USA.ORCID https://orcid.org/0000-0003-1464-5494

Funding

Genentech, Inc.
6 · The paper itself

Abstract

A high unmet need for novel, safe and effective therapies exists among older patients with non-Hodgkin lymphoma (NHL). We report safety and efficacy of mosunetuzumab in a subgroup analysis of a phase I/II study, which examined the prognostic impact of age in 218 patients with relapsed/refractory (R/R) B-cell NHL (B-NHL; ≥65 years, n = 102; <65 years, n = 116) from the phase I expansion cohort (NCT02500407) and further evaluated 90 patients with R/R follicular lymphoma (FL; ≥65 years, n = 30; <65 years, n = 60) from the pivotal cohort. The most common adverse event (AE) was cytokine release syndrome, occurring less frequently in older versus younger (33.3% vs. 44.8%) patients with B-NHL. Serious AEs were similar in older versus younger patients (45.1% vs. 46.6%). For patients with R/R FL, overall and complete response rates were numerically higher in older (86.7% and 70.0%, respectively) versus younger (76.7% and 55.0%) patients. Median progression-free survival and time-to-next treatment were 17.9 months and not reached in older patients versus 12.0 and 18.1 months in younger patients. These findings demonstrate mosunetuzumab is effective and well-tolerated across age groups in patients with R/R FL. Additional studies are warranted to further evaluate the safety and efficacy of mosunetuzumab in older patients with B-NHL.

Indexed as

Antibodies, Monoclonal, HumanizedAntineoplastic Agents, ImmunologicalLymphoma, FollicularAdultAgedAged, 80 and overAge FactorsFemaleHumansMaleMiddle AgedRecurrenceTreatment OutcomeAntibodies, Monoclonal, HumanizedAntineoplastic Agents, Immunologicalantibody therapyelderlyhaematological malignanciesnon‐Hodgkin lymphoma

Identifiers

PMID41254806
PMCPMC12819098

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.